Synthesis of Novel Thiazole/Thiadiazole Conjugates of Fluoroquinolones as Potent Antibacterial and Antimycobacterial Agents

dc.authorscopusid 59919743300
dc.authorscopusid 57190582389
dc.authorscopusid 56462977000
dc.authorscopusid 57193433153
dc.authorscopusid 57216239428
dc.authorscopusid 16481673500
dc.authorscopusid 59454839300
dc.contributor.author Poyraz Yılmaz, P.
dc.contributor.author Kulabaş, N.
dc.contributor.author Bozdeveci, A.
dc.contributor.author Vagolu, S.K.
dc.contributor.author Imran, M.
dc.contributor.author Tatar, E.
dc.contributor.author Küçükgüzel, İ.
dc.date.accessioned 2025-06-11T20:13:45Z
dc.date.available 2025-06-11T20:13:45Z
dc.date.issued 2025
dc.department Fenerbahçe University en_US
dc.department-temp [Poyraz Yılmaz P.] Institute of Health Sciences, Marmara University, İstanbul, Turkey; [Kulabaş N.] Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, İstanbul, Turkey; [Bozdeveci A.] Department of Biology, Faculty of Arts and Sciences, Recep Tayyip Erdoğan University, Rize, Turkey; [Vagolu S.K.] Department of Microbiology, University of Oslo, Oslo, Norway, Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway; [Imran M.] Center for Health Research, Northern Border University, Arar, Saudi Arabia; [Tatar E.] Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, İstanbul, Turkey, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İstanbul Kent University, İstanbul, Turkey; [Alpay Karaoğlu Ş.] Department of Biology, Faculty of Arts and Sciences, Recep Tayyip Erdoğan University, Rize, Turkey; [Sriram D.] Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Hyderabad, India; [Mahmood A.A.R.] Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq; [Küçükgüzel İ.] Institute of Health Sciences, Marmara University, İstanbul, Turkey, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Fenerbahçe University, İstanbul, Turkey en_US
dc.description.abstract Twenty azole-fluoroquinolone hybrids were designed and synthesized by conjugating thiazole and thiadiazole structures to ciprofloxacin and norfloxacin via a 2-oxoethyl bridge. The structures and purities of the synthesized compounds were proven by spectral techniques. The antimycobacterial effects of target compounds 21–40 were tested against Mycobacterium tuberculosis H37Rv strain. Among the 20 synthesized compounds, 12 exhibited minimal inhibition concentration (MIC) values in the range of 1.56–25 μg/mL. Among the molecules screened for antimycobacterial effects, the most effective was compound 35, a thiadiazole-ciprofloxacin hybrid. The cytotoxic effect of this molecule was found to be lower than the reference drugs, and it was also determined to be a more effective inhibitor than ciprofloxacin and norfloxacin in the DNA-gyrase supercoiling test. The antimicrobial effects of compounds 21–40 were screened by agar-well diffusion and microdilution tests against Gram-positive/negative bacteria, a fast-growing mycobacterium, and two yeast strains. While most of the compounds tested showed antibacterial effects, the most effective fluoroquinolone derivative appeared to be compound 31 with an MIC value of < 0.63 μg/mL against all Gram-negative bacteria tested. Azole-fluoroquinolone hybrids 21–40 did not show any activity against non-pathogenic Lactobacillus species and yeast-like fungi, indicating that they have selective antibacterial and antimycobacterial activity, particularly against Gram-negative bacteria. In silico molecular docking studies were conducted to uncover the interactions between lead compound 35 and the DNA gyrase proteins of M. tuberculosis and S. aureus. Additionally, a 100 ns molecular dynamics simulation was carried out to assess the stability of the complexes formed between compound 35 and both proteins. © 2025 The Author(s). Chemical Biology & Drug Design published by John Wiley & Sons Ltd. en_US
dc.description.sponsorship Institute of Organic Chemistry; Universität Heidelberg; Fine Chemicals Inc.; Marmara University Scientific Research Projects Commission; Atabay Pharmaceuticals; Marmara Üniversitesi, (SAG‐C‐DRP‐140115‐0002); Marmara Üniversitesi en_US
dc.description.woscitationindex Science Citation Index Expanded
dc.identifier.doi 10.1111/cbdd.70126
dc.identifier.issn 1747-0277
dc.identifier.issue 5 en_US
dc.identifier.pmid 40415348
dc.identifier.scopus 2-s2.0-105006547260
dc.identifier.scopusquality Q3
dc.identifier.uri https://doi.org/10.1111/cbdd.70126
dc.identifier.volume 105 en_US
dc.identifier.wos WOS:001494926800001
dc.identifier.wosquality Q3
dc.language.iso en en_US
dc.publisher John Wiley and Sons Inc en_US
dc.relation.ispartof Chemical Biology and Drug Design en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.scopus.citedbyCount 0
dc.subject Antibacterial Activity en_US
dc.subject Antituberculosis Activity en_US
dc.subject Dna-Gyrase en_US
dc.subject Fluoroquinolones en_US
dc.subject Molecular Docking en_US
dc.title Synthesis of Novel Thiazole/Thiadiazole Conjugates of Fluoroquinolones as Potent Antibacterial and Antimycobacterial Agents en_US
dc.type Article en_US
dc.wos.citedbyCount 0
dspace.entity.type Publication

Files